The radioactivity of the tumor was much higher than that of other organs, and tumor uptake was related to CD20 expression. The predicted human dose for the administration of Cu-DOTA-rituximab was measured as the effective dose (1.07E-02mSv/MBq). In the tumor region, equivalent doses of Ac-DOTA-rituximab (14 Sv /MBq) were much higher (74-fold) than those of Cu-DOTA-rituximab (0.19 Sv /MBq) (p < 0.01). Tumor dosimetry of Ac-DOTA-rituximab can be estimated via the Monte Carlo simulation of Cu-DOTA-rituximab. Ac-DOTA-rituximab can be employed for lymphoma as targeted alpha therapy. Tumor dosimetry of 225Ac-DOTA-rituximab can be estimated via the Monte Carlo simulation of 64Cu-DOTA-rituximab. 225Ac-DOTA-rituximab can be employed for lymphoma as targeted alpha therapy. Attenuation correction (AC) is crucial for ensuring the quantitative accuracy of positron emission tomography (PET) imaging. However, obtaining accurate μ-maps from brain-dedicated PET scanners without AC acquisition mechanism is challenging. Therefore, to overcome these problems, we developed a deep learning-based PET AC (deep AC) framework to synthesize transmission computed tomography (TCT) images from non-AC (NAC) PET images using a convolutional neural network (CNN) with a huge dataset of various radiotracers for brain PET imaging. The proposed framework is comprised of three steps (1) NAC PET image generation, (2) synthetic TCT generation using CNN, and (3) PET image reconstruction. https://www.selleckchem.com/products/avelestat-azd9668.html We trained the CNN by combining the mixed image dataset of six radiotracers to avoid overfitting, including [ F]FDG, [ F]BCPP-EF, [ C]Racropride, [ C]PIB, [ C]DPA-713, and [ C]PBB3. We used 1261 brain NAC PET and TCT images (1091 for training and 70 for testing). We did not include [ C]Methionine subjects in the ten using the CNN trained on the split dataset which means specific for each tracer. Nanoparticle albumin-bound paclitaxel (nab-PTX), a novel taxane formulation, was developed to avoid cremophor/ethanol-associated toxicities including peripheral neuropathy and hypersensitivity. At least 35 phase II studies using combined nab-PTX and anthracycline in neoadjuvant settings are registered in Japan. We analyzed the efficacy and safety of nab-PTX based on patient characteristics in these studies. We conducted a meta-analysis using individual patient data (IPD) to investigate the average efficacy of nab-PTX-containing regimens as neoadjuvant chemotherapy for operable breast cancer. IPD were provided by principal investigators who agreed to participate. The primary endpoint was pathological complete response (pCR) rate of each breast cancer subtype. We analyzed the data of 16 studies involving 753 patients. The overall crude frequencies of pCR (ypT0 ypN0, ypT0/is ypN0, and ypT0/is ypNX) were 18.1, 26.0, and 28.6%, respectively. Specifically, the frequencies were 6.7, 10.2, and 13.4% for luminal (n = 343); 40.5, 63.5, and 68.9% for human epidermal growth factor receptor 2 (HER2)-rich, (n = 74); 21.9, 40.6, and 42.7% for luminal/HER2 (n = 96); and 26.3, 31.5, and 32.3% for triple-negative breast cancers (TNBC) (n = 232). The multivariate analyses indicated that HER2 positivity, TNBC, high Ki-67, high nuclear grade, and weekly nab-PTX administration were significantly associated with the pCR. The proportion of hematological toxicities (neutropenia (39.7%) and leukopenia (22.5%)), peripheral sensory neuropathy (9.7%), myalgia (5.7%), and arthralgia (4.7%) was higher than grade 3 adverse events, but most patients recovered. Nab-PTX is a safe and acceptable chemotherapeutic agent in neoadjuvant settings, particularly for aggressive cancers. UMIN-CTR# UMIN000028774. Nab-PTX is a safe and acceptable chemotherapeutic agent in neoadjuvant settings, particularly for aggressive cancers. UMIN-CTR# UMIN000028774. To explore the capability of three-dimensional double-echo steady state with water excitation sequence (3D-DESS-WE) to determine the intraorbital ocular motor nerves (IOMN). A 3.0T scanner was applied to investigate 30 healthy volunteers based on the 3D-DESS-WE sequence. Dunnett t test was conducted to evaluate the signal intensity (SI) of the left oculomotor nerve (CNIII), frontal white matter, cerebrospinal fluid (CSF), and lateral rectus (LR). The oculomotor nerve's detectability, trochlear nerve (CNIV), and abducens nerve (CNVI) were evaluated independently by two observers. The average assessment scores were determined, and interobserver variability for these nerves' detectability was determined using a weighted kappa analysis. The SI of CNIII is similar to that of the frontal white matter (t = 2.26, P > 0.05), lower than the CSF, and higher than the LR (t = 3.81, - 3.45, P < 0.05). The average scores of the superior division of CNIII and the branch to medial rectus (MR), inferior rectus (IR), inferior oblique (IO), CNIV, and CNVI were 3.01, 3.07, 3.78, 2.98, 2.88, and 3.97, respectively. The interobserver variability was excellent (κ = 0.83-1.00). The 3D-DESS-WE sequence shows an ability to detect the IOMN course in healthy volunteers effectively. The 3D-DESS-WE sequence shows an ability to detect the IOMN course in healthy volunteers effectively.The fatality rate of ovarian cancer ranks first among gynecological tumors, and the prognosis is poor. Diosmetin (Dio), a natural flavonoid obtained from citrus fruits, has been shown to have anti-tumor effects in lung, liver, and skin cancers. We aimed to investigate the effects of Dio on ovarian cancer A2780 and SKOV3 cells along with the underlying mechanisms. Our data showed that Dio inhibited the proliferation, migration, and invasion of these cells and induced their apoptosis. Moreover, Dio upregulated the levels of Bax and cleaved Caspase-3 and PARP while downregulating the level of Bcl2. Mechanistically, our results revealed that Dio inhibited Nrf2 and induced the production of reactive oxygen species (ROS). The ROS scavenger N-acetyl-L-cysteine (NAC) suppressed the inhibitory effect of Dio on the proliferation of the ovarian cancer cells. Additionally, overexpression of Nrf2 partially suppressed the Dio-induced apoptosis and proliferation inhibition in these cells. These findings indicate that Dio exerts an anti-tumor activity by upregulating ROS levels and inhibiting Nrf2, indicating that Dio is a promising chemotherapeutic candidate for the treatment of ovarian cancer.